MX2022010781A - Cpg-adjuvanted sars-cov-2 virus vaccine. - Google Patents

Cpg-adjuvanted sars-cov-2 virus vaccine.

Info

Publication number
MX2022010781A
MX2022010781A MX2022010781A MX2022010781A MX2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A
Authority
MX
Mexico
Prior art keywords
adjuvanted
cov
sars
cpg
virus vaccine
Prior art date
Application number
MX2022010781A
Other languages
Spanish (es)
Inventor
Robert Schlegl
Christoph Reinisch
Robert S Janssen
Andreas Meinke
Jürgen Heindl-Wruss
John D Campbell
David Novack
Michael Möhlen
Christian Taucher
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Priority claimed from PCT/IB2021/052858 external-priority patent/WO2021176434A1/en
Publication of MX2022010781A publication Critical patent/MX2022010781A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
MX2022010781A 2020-04-06 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine. MX2022010781A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202124 2020-10-15
EP20211936 2020-12-04
EP21154645 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160933 2021-03-05
PCT/IB2021/052858 WO2021176434A1 (en) 2020-03-01 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine

Publications (1)

Publication Number Publication Date
MX2022010781A true MX2022010781A (en) 2023-03-09

Family

ID=83887208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010781A MX2022010781A (en) 2020-04-06 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine.

Country Status (4)

Country Link
KR (1) KR20230005814A (en)
CN (1) CN115666633A (en)
CA (1) CA3168783A1 (en)
MX (1) MX2022010781A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432437A (en) * 2022-01-07 2022-05-06 广东粤港澳大湾区国家纳米科技创新研究院 Application of mangano-manganic oxide particles in preparation of vaccine adjuvant
CN116983401A (en) * 2023-06-29 2023-11-03 贝湾生物科技有限公司 New coronal booster vaccine based on SARS1 virus

Also Published As

Publication number Publication date
CA3168783A1 (en) 2021-09-10
CN115666633A (en) 2023-01-31
KR20230005814A (en) 2023-01-10

Similar Documents

Publication Publication Date Title
MX2018007627A (en) Zika virus vaccine.
WO2021204825A3 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
ECSP22072586A (en) VACCINE AGAINST SARS-CoV-2 VIRUS WITH CpG ADJUVANT
MX2022010781A (en) Cpg-adjuvanted sars-cov-2 virus vaccine.
MX344596B (en) Recombinant subunit dengue virus vaccine.
MX2021001762A (en) Method and composition for stimulating immune response.
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EA202090967A1 (en) STABLE VACCINE COMPOSITIONS INCLUDING, IN PARTICULAR, LIVING ATTENUATED RECOMBINANT FLAVIVIRUS, AND THEIR PREPARATION PROCESS
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2016007726A (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon.
EA201690057A1 (en) OSTEOPONTIN MILK MAMMALS TO IMPROVE IMMUNOLOGICAL REACTIVITY
BR112022020298A2 (en) VACCINES, ADJUVANTS AND METHODS TO GENERATE AN IMMUNE RESPONSE
MX2022012447A (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE.
EA202190914A1 (en) IMMUNOGENIC COMPOSITIONS
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
MX2023004016A (en) Herpesvirus polyepitope vaccines.
MX2022004869A (en) Chikungunya virus-like particle vaccine and methods of using the same.
AR121752A1 (en) INACTIVATED VACCINE AGAINST SARS-CoV-2 VIRUS
MX2023000097A (en) Vaccine adjuvants and methods of synthesizing and using the same.
WO2024068265A3 (en) Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
ZA202300164B (en) Modified alphavirus for use as covid-19 vaccine
MX2022001430A (en) Chikungunya vaccine formulations.
WO2022256637A3 (en) Synthetic dna vaccine immunogenic improvements
EA202090386A1 (en) METHODS AND COMPOSITIONS FOR HETEROLOGICAL IMMUNIZATION REPRNA